US007732491 B2 (12) UnitedO States Patent (10) Patent No.: US 7,732.491 B2 Sherman et al. (45) Date of Patent: Jun. 8, 2010 (54) TREATMENT OF BREAST CANCER WITH A 5,516,941 A 5/1996 Kun et al. PARP INHIBITOR ALONE OR IN 5,519,053 A 5/1996 Kun et al. COMBINATION WITH ANT-TUMIOR 5,583,155 A 12/1996 Kun et al. AGENTS 5,631,038 A 5/1997 Kurtz et al. 5,631,231 A 5/1997 Kurtz et al. (75) Inventors: Barry M. Sherman, Hillsborough, CA E. 2. I al (US); Charles Bradley, Half Moon Bay, 5,631,252 A 5/1997 Kurtz et al. CA (US); Valeria S. Ossovskaya, San 5,631,272 A 5/1997 Kurtz et al. Francisco, CA (US) 5,631,292 A 5/1997 Kurtz et al. 5,631,294 A 5/1997 Kurtz et al. (73) Assignee: BiPar Sciences, Inc., Brisbane, CA (US) 5,631,295 A 5/1997 Kurtz et al. 5,631,299 A 5/1997 Kurtz et al. (*) Notice: Subject to any disclaimer, the term of this 5,633,282 A 5/1997 Collins et al. patent is extended or adjusted under 35 5,637,618 A 6/1997 Kurtz et al. U.S.C. 154(b) by 0 days. 5,639,788 A 6/1997 Kurtz et al. 5,641,795. A 6/1997 Kurtz et al. 5,641,799 A 6/1997 Kurtz et al. (21) Appl. No.: 12/269,024 5,641,811 A 6/1997 Kurtz et al. 1-1. 5,641,812 A 6/1997 Kurtz et al. (22) Filed: Nov. 11, 2008 5,643,894. A 7/1997 Kurtz et al. O O 5,643,941 A 7/1997 Kurtz et al. (65) Prior Publication Data 5,643,945. A 7/1997 Kurtz et al. US 2009/0131529 A1 May 21, 2009 5,643,955. A 7/1997 Kurtz et al. 5,643,956 A 7/1997 Kurtz et al. Related U.S. Application Data 5,646,122 A 7/1997 Kurtz et al. (60) Provisional application No. 60/987,333, filed on Nov. (Continued) 12, 2007, provisional application No. 61/012,364, filed on Dec. 7, 2007, provisional application No. FOREIGN PATENT DOCUMENTS 61/058,528, filed on Jun. 3, 2008. CN 1768732 A S/2006 (51) Int. Cl. (Continued) A6 IK3I/I66 2006.O1 (52) U.S. Cl ( ) S14f619 OTHER PUBLICATIONS (58) Field of Classification Search .................. 514f619 Dent et al. Clin. Cancer Res., 2007, vol. 13, No. 15, pp. 4429-4434.* See application file for complete search history. Cleator et al. Lancet Oncol., 2007, vol. 8, pp. 235-244.* Irvin et al. European Journal of Cancer, 2008, vol. 44, pp. 2799 (56) References Cited 2805.* DeSoto et al. International Journal of Medical Sciences, 2006, vol. 3, U.S. PATENT DOCUMENTS No. 4, pp. 117-123.* 2006.735. A 7, 1935 Fischer at all Donawho et al. Clin. Cancer Res., 2007, vol. 13, No. 9, pp. 2728 2737.* 2S25 A 38. inal Ausubel, et al. Current Protocols of Molecular Biology, John Wiley 3,161,564. A 12/1964 Morehouse and Sons (1997). 3.228,833. A 1, 1966 Crounseat al. Ayhan, his Topotecan as t Second-line E. with 4 4-w ovarian and primary peritoneal cancer: initial response and long-term s: A 8. My et al. follow-up. Eur J. Gynaecol Oncol. 2006:27(6):603-6. 5041. 653 A 8, 1991 Lee et al. Berchuck, et al. Overexpression of HER-2/neu in endometrial cancer 5.62532 A 11/1992 Comins et al is associated with advanced stage disease. Am J ObstetGynecol. Jan. 5,177,075 A 1/1993 Suto et al. 1991; 164(1 Pt 1): 15-21. 5, 191,082 A 3, 1993 Comins et al. (Continued) 5,200,524 A 4, 1993 Comins et al. 5,215,738 A 6, 1993 Lee et al. Primary Examiner James D Anderson 5,223,608 A 6, 1993 Chou et al. (74) Attorney, Agent, or Firm Morrison & Foerster LLP 5,232,735 A 8, 1993 Kurtz et al. 5,243,050 A 9, 1993 Comins et al. (57) ABSTRACT 5,247,089 A 9, 1993 Comins et al. 5,262,564 A 11/1993 Kun et al. In one aspect, the present invention provides a method of 532,1405.283.352 A 6,2f1994 1994 ComiBäckström et1 all treating breast cancer that is negative for at least one of ER, 5.420. 319 A 5, 1995 OWs et al PR, or HER2, comprising administering to a subject at least 5.434.2 54 A 7, 1995 t one PARP inhibitor. In another aspect, the present invention 5.464.87 1 A 11/1995 Kun et all provides a method of treating breast cancer comprising 5.473,074 A 12/1995 Kunet al. administering to a subject at least one PARP inhibitor in 5482,833 A 1/1996 Pero et al. combination with at least one anti-tumor agent. 5,482.975 A 1/1996 Kun et al. 5,484.951 A 1/1996 Kun et al. 10 Claims, 6 Drawing Sheets US 7,732.491 B2 Page 2 U.S. PATENT DOCUMENTS 2005/0059824 A1 3/2005 Vaidyanathan et al. 2005, 0080.096 A1 4, 2005 Ishida et al. 5,650,403 A 7, 1997 Kurtz et al. 2005/0113283 A1 5/2005 Solow-Cordero et al. 5,652,260 A 7, 1997 Kun et al. 2005/017103.6 A1 8/2005 Arakawa et al. 5,652,367 A 7, 1997 Kun et al. 2005/0171101 A1 8/2005 Yamamoto et al. 5,654,311 A 8, 1997 Kurtz et al. 2005/0227919 A1 10, 2005 Ashworth et al. 5,665,755 A 9, 1997 Kurtz et al. 2005/0287120 A1 12/2005 Fisher et al. 5,670,518 A 9, 1997 Kun et al. 2006, OO63767 A1 3, 2006 Javaid et al. 5,700,792 A 12/1997 Kurtz et al. 2006/0074073 A1 4/2006 Steinfeldt et al. 5,703,053 A 12/1997 Kurtz et al. 2006/0094676 A1 5.2006 Lahav et al. 5,719,151 A 2f1998 Shall et al. 2006/0100198 A1 5.2006 Liu et al. 5,734,056 A 3, 1998 Burk et al. 2006/0229289 A1 10, 2006 Zhu et al. 5,736,576 A 4, 1998 Kun et al. 2006/0229.351 A1 10, 2006 Zhu et al. 5,753,674. A 5, 1998 Kun et al. 2007, OO15814 A1 1/2007 Kun et al. 5,756,510 A 5, 1998 Griffin et al. 2007,0265324 A1 11/2007 Wernet et al. 5,770.599 A 6, 1998 Gibson 2007/0281948 A1 12/2007 Peukert et al. 5,783,599 A 7, 1998 Kun et al. 2007/0292883 Al 12/2007 Ossovskaya et al. 5,837,729 A 11/1998 Bourinbaiar 2008.OO25990 A1 1/2008 Ludwig 5,866,608 A 2f1999 Kurtz et al. 2008/0039633 A1 2/2008 Jung et al. 5,874.444 A 2, 1999 West 2008/0076778 A1 3/2008 Ossovskaya et al. 5,877, 185 A 3, 1999 Kun et al. 2008/0.103104 A1 5/2008 Moore et al. 5,908,861 A 6, 1999 Kun 2008/0103208 A1 5/2008 Ossovskaya et al. 5,922,775 A 7, 1999 Kun et al. 2008.0167345 A1 7/2008 Jones et al. 5,959,133 A 9, 1999 Ohnishi 2008/0176946 A1 7/2008 Ossovskaya et al. 6,004,978 A 12/1999 Kun et al. 2008/0262062 A1 10/2008 Ossovskaya et al. 6,008,250 A 12/1999 Kurtz et al. 2008/0293795 A1 11/2008 Donawho et al. 6,015,792 A 1/2000 Kurtz et al. 2008/0319054 A1 12/2008 Kun et al. 6,015,827 A 1/2000 Griffin et al. 2009/0076122 A1 3, 2009 Kun et al. 6,017,958 A 1/2000 Kun et al. 2009/0123419 A1 5/2009 Sherman et al. 6,100,283 A 8, 2000 Griffin et al. 2009/0149397 A1 6/2009 Ossovskaya et al. 6,121,278 A 9, 2000 Jackson et al. 2009/01494.17 A1 6/2009 Ossovskaya et al. 6,156,739 A 12/2000 Griffin et al. 2009/0291924 A1 1 1/2009 Ossovskaya et al. 6,169,104 B1 1/2001 Tuse et al. 6,201,020 B1 3/2001 Zhang et al. FOREIGN PATENT DOCUMENTS 6,235,748 B1 5/2001 Lietal. 6,277,990 B1 8/2001 Jagtap et al. CN 1768732 A 5, 2006 6,303,629 B1 10/2001 Kun CN 1768733. A 5, 2006 6,310,082 B1 10/2001 Griffin et al. CN 1768733. A 5, 2006 6,316,455 B1 1 1/2001 Griffin et al. CN 101 190211 A 6, 2008 6,316,495 B1 1 1/2001 Kun et al. CN 101 190211 A 6, 2008 6,326,517 B1 12/2001 Kume et al. EP O 84.1924 B1 5, 1998 6,380,193 B1 4/2002 Li et al. EP 1127 052 B1 8/2001 6,387.902 B1 5/2002 Zhang et al. EP 1348 432 A1 10, 2003 6,395,749 B1 5/2002 Lietal. EP 1082416 B1 3f2007 6,407,079 B1 6/2002 Müller et al. FR 2456 731 A 1, 1971 6,423,696 B1 7/2002 Collins et al. GB 1463 575 2, 1977 6,426,415 B1 7/2002 Jackson et al. GB 2447 796 B 3, 2009 6,448,271 B1 9/2002 Lubisch et al. JP 2000, 191612 A T 2000 6,476,048 B1 1 1/2002 Szabo et al.